MBX Stock Overview
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally.
Microbix Biosystems Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.52|
|52 Week High||CA$0.87|
|52 Week Low||CA$0.43|
|1 Month Change||-1.89%|
|3 Month Change||-13.33%|
|1 Year Change||-10.35%|
|3 Year Change||48.57%|
|5 Year Change||60.00%|
|Change since IPO||-13.33%|
Recent News & Updates
Microbix Biosystems' (TSE:MBX) Solid Profits Have Weak Fundamentals
Unsurprisingly, Microbix Biosystems Inc.'s ( TSE:MBX ) stock price was strong on the back of its healthy earnings...
|MBX||CA Biotechs||CA Market|
Return vs Industry: MBX exceeded the Canadian Biotechs industry which returned -23.3% over the past year.
Return vs Market: MBX underperformed the Canadian Market which returned 4.9% over the past year.
|MBX Average Weekly Movement||7.1%|
|Biotechs Industry Average Movement||10.0%|
|Market Average Movement||9.8%|
|10% most volatile stocks in CA Market||17.0%|
|10% least volatile stocks in CA Market||4.4%|
Stable Share Price: MBX is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MBX's weekly volatility (7%) has been stable over the past year.
About the Company
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.
Microbix Biosystems Fundamentals Summary
|MBX fundamental statistics|
Is MBX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MBX income statement (TTM)|
|Cost of Revenue||CA$7.79m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.028|
|Net Profit Margin||18.78%|
How did MBX perform over the long term?See historical performance and comparison
Is Microbix Biosystems undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MBX (CA$0.52) is trading above our estimate of fair value (CA$0)
Significantly Below Fair Value: MBX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MBX is poor value based on its PE Ratio (18.3x) compared to the Canadian Biotechs industry average (10.4x).
PE vs Market: MBX is poor value based on its PE Ratio (18.3x) compared to the Canadian market (11.4x).
Price to Earnings Growth Ratio
PEG Ratio: MBX is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: MBX is overvalued based on its PB Ratio (3x) compared to the CA Biotechs industry average (2.5x).
How is Microbix Biosystems forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBX's forecast earnings growth (24.4% per year) is above the savings rate (1.6%).
Earnings vs Market: MBX's earnings (24.4% per year) are forecast to grow faster than the Canadian market (7.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MBX's revenue (5% per year) is forecast to grow slower than the Canadian market (6.4% per year).
High Growth Revenue: MBX's revenue (5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MBX's Return on Equity is forecast to be high in 3 years time
How has Microbix Biosystems performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MBX has a high level of non-cash earnings.
Growing Profit Margin: MBX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MBX has become profitable over the past 5 years, growing earnings by 23.9% per year.
Accelerating Growth: MBX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MBX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (95.3%).
Return on Equity
High ROE: MBX's Return on Equity (16.4%) is considered low.
How is Microbix Biosystems's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MBX's short term assets (CA$23.1M) exceed its short term liabilities (CA$3.6M).
Long Term Liabilities: MBX's short term assets (CA$23.1M) exceed its long term liabilities (CA$5.6M).
Debt to Equity History and Analysis
Debt Level: MBX has more cash than its total debt.
Reducing Debt: MBX's debt to equity ratio has reduced from 44.7% to 22% over the past 5 years.
Debt Coverage: MBX's debt is well covered by operating cash flow (29.5%).
Interest Coverage: MBX's interest payments on its debt are well covered by EBIT (3.6x coverage).
What is Microbix Biosystems's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MBX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MBX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MBX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Cameron L. Groome serves as an Independent Director at iFabric Corp. since March 30, 2020. Mr. Groome has been the Chief Executive Officer and President of Microbix Biosystems Inc. since July 24, 2017....
CEO Compensation Analysis
Compensation vs Market: Cameron's total compensation ($USD465.50K) is above average for companies of similar size in the Canadian market ($USD168.65K).
Compensation vs Earnings: Cameron's compensation has been consistent with company performance over the past year.
Experienced Management: MBX's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: MBX's board of directors are seasoned and experienced ( 15.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MBX insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.1%.
Microbix Biosystems Inc.'s employee growth, exchange listings and data sources
- Name: Microbix Biosystems Inc.
- Ticker: MBX
- Exchange: TSX
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$71.392m
- Shares outstanding: 137.29m
- Website: https://microbix.com
Number of Employees
- Microbix Biosystems Inc.
- 265 Watline Avenue
- L4Z 1P3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.